Amneal Pharmaceuticals Inc (NASDAQ: AMRX) on Tuesday, soared 3.63% from the previous trading day, before settling in for the closing price of $8.26. Within the past 52 weeks, AMRX’s price has moved between $5.01 and $9.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 10.36%. The company achieved an average annual earnings per share of -3.91%. With a float of $126.78 million, this company’s outstanding shares have now reached $309.77 million.
The extent of productivity of a business whose workforce counts for 7850 workers is very important to gauge. In terms of profitability, gross margin is 35.34%, operating margin of 7.0%, and the pretax margin is -4.59%.
Amneal Pharmaceuticals Inc (AMRX) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Amneal Pharmaceuticals Inc is 59.08%, while institutional ownership is 41.81%. The most recent insider transaction that took place on Jan 08 ’25, was worth 501,346. In this transaction Director of this company sold 62,590 shares at a rate of $8.01, taking the stock ownership to the 1,968,886 shares. Before that another transaction happened on Jan 02 ’25, when Company’s Director sold 17,410 for $8.01, making the entire transaction worth $139,454. This insider now owns 2,031,476 shares in total.
Amneal Pharmaceuticals Inc (AMRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.91% per share during the next fiscal year.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
Amneal Pharmaceuticals Inc (AMRX) is currently performing well based on its current performance indicators. A quick ratio of 0.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.99. Likewise, its price to free cash flow for the trailing twelve months is 26.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.68, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Amneal Pharmaceuticals Inc (AMRX)
The latest stats from [Amneal Pharmaceuticals Inc, AMRX] show that its last 5-days average volume of 1.42 million was superior to 1.22 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 85.55%. Additionally, its Average True Range was 0.27.
During the past 100 days, Amneal Pharmaceuticals Inc’s (AMRX) raw stochastic average was set at 53.20%, which indicates a significant decrease from 96.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.96% in the past 14 days, which was higher than the 30.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.23, while its 200-day Moving Average is $7.58. Now, the first resistance to watch is $8.67. This is followed by the second major resistance level at $8.79. The third major resistance level sits at $8.98. If the price goes on to break the first support level at $8.36, it is likely to go to the next support level at $8.17. Assuming the price breaks the second support level, the third support level stands at $8.05.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Key Stats
Market capitalization of the company is 2.65 billion based on 309,844K outstanding shares. Right now, sales total 2,394 M and income totals -83,990 K. The company made 702,470 K in profit during its latest quarter, and -160 K in sales during its previous quarter.
